https://trial.medpath.com/news/biohaven-announces-third-quarter-2024-financial-results-and-business-developments 2024-11-12T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucl-spinout-autolus-gains-us-approval-for-cancer-therapy 2024-11-12T20:58:54+00:00 weekly 0.7 https://trial.medpath.com/news/dyne-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-12T20:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-11-12T20:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2024-11-12T20:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-announces-koselugo-met-primary-endpoing-in-komet-phase-iii-trial 2024-11-12T20:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-plans-pivotal-trial-for-ai-based-ipf-candidate 2024-11-12T20:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-suggests-weight-loss-drugs-like-ozempic-could-help-with-knee-pain-here-s-why 2024-11-12T19:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-cohort-in-augment-101-trial-of-revumenib 2024-11-12T19:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/drug-for-infertility-puberty-disorders-hot-flashes-soon-us-scientist-times-of-india 2024-11-12T19:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-s-pimicotinib-meets-endpoints-in-phase-iii-bioworld 2024-11-12T19:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio 2024-11-12T19:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-submit-biologics-license-application-of-datopotamab 2024-11-12T18:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-wins-fda-ide-for-ottava-surgical-robot-massdevice 2024-11-12T18:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-eurekalert 2024-11-12T18:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-announced-positive-phase-1-results-for-its-oral-glp-yahoo-finance 2024-11-12T18:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/prokidney-reports-third-quarter-2024-financial-results-globenewswire 2024-11-12T18:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-autolus-aucatzyl-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-12T18:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-ohio-state-medical-center 2024-11-12T18:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-holding-corp-sec-10-q-report-tradingview 2024-11-12T18:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-11-12T18:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma 2024-11-12T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-ocaliva-full-approval-in-primary-biliary-cholangitis-safety-data-still-in-play 2024-11-12T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/indaptus-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/naim-alkhouri-md-first-real-world-data-for-resmetirom-use-in-clinical-practice-hcplive 2024-11-12T18:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-for-npm1-mutant-aml-succeeds-in-pivotal-trial-targeted-oncology 2024-11-12T18:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/key-clinical-compound-updates-from-october-2024 2024-11-12T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-cases-in-bluebird-s-gene-therapy-trials-nature-biotechnology 2024-11-12T17:41:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ai-procured-ism001-055-demonstrates-great-promise-for-treatment-of-ipf 2024-11-12T17:36:25+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-reports-results-from-trial-of-cvn293-for-neurodegenerative-conditions 2024-11-12T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-combined-covid-19-influenza-vaccine-trials 2024-11-12T17:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-reports-third-quarter-2024-globenewswire 2024-11-12T17:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-s-pimicotinib-hits-primary-endpoint-in-phase-3-tgct-trial 2024-11-12T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/eu-crunch-time-for-kizfizo-sipavibart-coacillium-eight-other-products 2024-11-12T17:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/qnrx-international-sites-participating-in-qrx003-ns-study-zacks-small-cap-research 2024-11-12T17:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division-abc-news 2024-11-12T17:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-ottava-surgical-robot-to-begin-clinical-trial-after-fda-nod-medtech-dive 2024-11-12T17:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-meets-orr-end-point-in-tenosynovial-giant-cell-tumor-onclive 2024-11-12T17:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-framework-for-n-of-1-trials-of-individualized-gene-targeted-therapies-for-genetic-diseases 2024-11-12T17:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-hits-a-setback-in-the-clinic-days-after-fundraise-biopharma-dive 2024-11-12T17:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-12T17:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/entinostat-in-combination-with-nivolumab-in-metastatic-pancreatic-ductal-adenocarcinoma 2024-11-12T17:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/uf-health-study-to-assess-pharmacogenetic-testing-in-the-er 2024-11-12T17:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/immuno-cure-biotech-presents-promising-results-on-phase-i-clinical-trial-of-a-therapeutic 2024-11-12T17:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/casting-a-wide-net-when-is-the-optimal-time-for-177lu-dotatate-treatment 2024-11-12T17:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-new-bla-for-dato-dxd-in-advanced-egfr-nsclc-cancer-network 2024-11-12T17:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-resubmission-for-epidermolysis-bullosa-gene-therapy-drug-topics 2024-11-12T16:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-investors-including-third-rock-pump-100m-into-a-startup-s-genetic-medicine-for-als 2024-11-12T16:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-pfa-trial-in-new-patient-group-after-pausing-enrollment 2024-11-12T16:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-nipocalimab-for-sjogren-s-disease-healio 2024-11-12T16:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-for-donidalorsen-healio 2024-11-12T16:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/dmts-are-major-clinical-research-focus-for-parkinson-s-disease-analysis-shows 2024-11-12T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-revise-approval-plans-for-enhertu-successor-biopharma-dive 2024-11-12T16:26:24+00:00 weekly 0.7 https://trial.medpath.com/news/sareum-holdings-edison-vox-markets 2024-11-12T16:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/formation-bio-collaborates-with-openai-and-sanofi-to-introduce-muse-marketscreener 2024-11-12T16:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/one-genomic-test-can-diagnose-nearly-any-infection-uc-san-francisco 2024-11-12T16:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/peta-the-oncostory-that-started-when-he-was-four-months-old-the-university-hospital-brno 2024-11-12T15:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T15:57:18+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-fda-green-light-for-robotic-system-trial-marketscreener 2024-11-12T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/nevro-wins-ce-mark-for-hfx-iq-spinal-cord-stim-for-pain-relief-massdevice 2024-11-12T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/magstim-earns-fda-clearance-for-transcranial-magnetic-stimulation-that-treats-depression-ocd 2024-11-12T15:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combo-vaccine 2024-11-12T15:37:30+00:00 weekly 0.7 https://trial.medpath.com/news/merck-drug-for-rare-tumour-hits-phase-3-target-pharmaphorum 2024-11-12T15:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-pfizer-used-wearables-to-tap-into-the-promise-of-an-experimental-drug-stat-news 2024-11-12T15:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-triplet-therapy-for-advanced-stage-pik3ca-mutant-hr-breast-cancer-improves-outcomes 2024-11-12T15:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/buy-sell-or-hold-bmy-stock-forbes 2024-11-12T15:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T15:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/prominent-usc-scientist-goes-on-leave-amid-research-misconduct-allegations-national 2024-11-12T15:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/zolbetuximab-plus-chemotherapy-offers-survival-benefits-in-treatment-naive-her2-onclive 2024-11-12T15:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-doses-first-subject-in-trial-of-acute-kidney-injury-treatment 2024-11-12T15:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-scanning-of-genetic-variants-with-base-and-prime-editing-nature-biotechnology 2024-11-12T15:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/seattle-children-s-now-enrolling-participants-for-first-u-s-car-t-cell-clinical-trial-for 2024-11-12T14:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-final-call-on-alzheimer-s-drug-leqembi-imminent-citeline 2024-11-12T14:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct 2024-11-12T14:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-of-work-an-atypical-schizophrenia-drug-is-approved 2024-11-12T14:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/refined-definition-of-platinum-resistance-novel-adcs-could-brind-more-changes-to-onclive 2024-11-12T14:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/komet-phase-iii-trial-met-primary-endpoint-shares-magazine 2024-11-12T14:22:23+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-givlaari-r-swissmedic 2024-11-12T14:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-crl-to-obeticholic-acid-ocaliva-denies-full-approval-for-pbc-hcplive 2024-11-12T14:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-therapeutics-highlights-presentation-at-european-yahoo-finance 2024-11-12T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-disappointing-schizophrenia-drug-trial-bodes-well-for-rival-bristol-myers-analysts-say 2024-11-12T14:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-s-tecarfarin-shows-promise-for-lvad-patients-in-key-medical-congress-data 2024-11-12T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/woolsey-pharmaceuticals-completes-patient-recruitment-for-high-dose-cohort-of-als-study 2024-11-12T14:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-therapeutics-highlights-presentation-at-european-placera 2024-11-12T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-initiates-phase-3-deep-ocean-study-evaluating-bexicaserin 2024-11-12T13:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-unit-gets-ema-nod-for-biosimilar-facility-the-week 2024-11-12T13:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-globenewswire 2024-11-12T13:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T13:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/acuitive-technologies-receives-fda-510-k-clearance-for-globenewswire 2024-11-12T13:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/icad-s-profound-detection-version-4-0-gains-fda-clearance-globenewswire 2024-11-12T13:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/savara-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T13:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-submits-eu-and-us-applications-for-subcutaneous-darzalex-in-smouldering-multiple-myeloma 2024-11-12T13:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized 2024-11-12T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T13:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-breakthrough-fda-fast-track-cancer-drug-advances-to-pivotal-phase-3-trial 2024-11-12T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-s-allocetra-advances-phase-ii-trial-launches-for-knee-osteoarthritis-treatment 2024-11-12T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-12T13:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T13:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T13:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-pr-newswire 2024-11-12T12:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-announces-fda-clinical-hold-lift-on-phase-3-covid-19-flu-vaccine-study-pmlive 2024-11-12T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T12:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update 2024-11-12T12:34:20+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-s-ibd-drug-shows-breakthrough-90-day-half-life-in-phase-1-trial-4x-better-than-standard 2024-11-12T12:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-r-announces-fda-acceptance-of-bla-globenewswire 2024-11-12T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/momentis-surgical-gets-fda-approval-for-second-generation-anovo-robotic-platform 2024-11-12T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/exostat-medical-receives-fda-clearance-for-novel-real-time-oral-tissue-perfusion 2024-11-12T12:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/multiomic-health-announces-discovery-of-novel-endotypes-and-biomarkers-for-diabetic 2024-11-12T12:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T12:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-regulator-raises-red-flag-on-clinical-trial-bribery-citeline 2024-11-12T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-12T12:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/zenas-biopharma-hits-milestone-completes-enrollment-in-largest-ever-igg4-rd-trial 2024-11-12T12:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-news-medical 2024-11-12T12:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-provides-corporate-update-and-globenewswire 2024-11-12T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytics-biotech-r-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T12:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:07:44+00:00 weekly 0.7 https://trial.medpath.com/news/bioxcel-therapeutics-advances-pivotal-phase-3-trials-of-globenewswire 2024-11-12T12:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-12T12:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/formation-bio-collaborates-with-sanofi-and-openai-to-introduce-muse-a-first-of-its-kind-ai 2024-11-12T12:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T12:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients 2024-11-12T12:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-announces-third-quarter-2024-financial-results-and-recent-corporate-updates 2024-11-12T11:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-change-strategy-on-closely-watched-cancer-drug-stat-news 2024-11-12T11:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/show-chwan-health-care-system-joins-novotech-to-accelerate-the-quality-of-clinical-leader 2024-11-12T11:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/koselugo-r-selumetinib-showed-significant-and-clinically-meaningful-improvement-in 2024-11-12T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-phase-3-enrollment-for-novel-acne-drug-building-on-phase-2-success 2024-11-12T11:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T11:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-shares-results-from-trial-of-dovato-and-three-drug-therapy-for-hiv 2024-11-12T11:33:07+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-launches-awareness-campaign-for-fcs 2024-11-12T11:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/rowan-based-startup-receives-fda-clearance-for-medical-technology 2024-11-12T11:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/scientific-leadership-spotlighted-as-gilead-presents-research-data-across-its-broad-and 2024-11-12T10:45:47+00:00 weekly 0.7 https://trial.medpath.com/news/lipella-pharmaceuticals-secures-extended-market-exclusivity-globenewswire 2024-11-12T10:32:25+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-proud-but-not-revived-by-autolus-winning-fda-approval-citywire 2024-11-12T10:26:11+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-car-t-aucatzyl-wins-us-fda-nod-for-leukemia-bioworld 2024-11-12T10:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionising-heart-health-frontier-x-plus-gains-fda-approval-aw-athletics-weekly 2024-11-12T10:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-j-j-s-nipocalimab-for-sjd-treatment 2024-11-12T09:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/astra-invests-3-5-billion-in-us-as-cancer-drug-lifts-sales-bnn-bloomberg 2024-11-12T09:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-phase-iii-trial-of-pimicotinib-in-tenosynovial-giant-cell-tumor-meets-primary-endpoint 2024-11-12T09:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-gets-fda-breakthrough-status-tradingview 2024-11-12T08:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/tdf-litigation-gilead-sciences 2024-11-12T08:40:24+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-koselugo-phase-iii-trial-meets-primary-goal-in-adults-with-neurofibromatosis-type-1 2024-11-12T08:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/nanobiotix-provides-third-quarter-2024-update-and-progress-on-nanotherapeutics-platforms 2024-11-12T07:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/koselugo-showed-statistically-significant-and-clinically-meaningful-objective-response-rate 2024-11-12T07:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-announces-u-s-food-and-drug-administration-grants-nipocalimab 2024-11-12T07:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-12T06:38:10+00:00 weekly 0.7 https://trial.medpath.com/news/relacorilant-plus-nab-paclitaxel-carves-new-avenues-of-platinum-resistant-ovarian-cancer-care 2024-11-12T06:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-12T06:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-analysis-shows-tafinlar-plus-mekinist-reduces-mortality-risk-in-stage-iii-melanoma 2024-11-12T06:17:59+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-clinical-trial-efficiency-the-power-of-simplicity-for-first-in-human-studies 2024-11-12T06:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/kancera-focuses-on-cardiovascular-diseases-placera 2024-11-12T06:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/early-treatment-of-hepatitis-b-is-key-to-preventing-liver-cancer-and-reducing-healthcare-costs 2024-11-12T05:50:45+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-clinical-trial-of-pembrolizumab-and-denileukin-diftitox-in-patients-with-recurrent 2024-11-12T05:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/organogenesis-phase-3-trial-success-renu-knee-treatment-shows-promising-results 2024-11-12T05:05:25+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-marketscreener 2024-11-12T03:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/recordati-s-isturisa-wins-korean-approval-to-treat-cusing-s-disease-pharma-article-kbr 2024-11-12T02:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-behind-the-insider-buying-on-this-high-yield-stock-the-globe-and-mail 2024-11-12T01:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-12T00:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-regulator-raises-red-flag-on-clinical-trial-bribery 2024-11-12T00:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/allo-316-shows-50-response-rate-in-cd70-positive-rcc-in-phase-1-trial 2024-11-12T00:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-gets-breakthrough-therapy-designation-for-sjogren-s-disease-treatment 2024-11-12T00:00:16+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-launches-asia-s-first-mrna-biofoundry-to-advance-nucleic-acid-therapeutics 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cogent-biosciences-reports-recent-business-highlights-and-third-quarter-2024-financial-results 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-lymphir-and-keytruda-combo-shows-promising-clinical-outcomes-earning-a-buy-rating 2024-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-novavax-s-trials-for-covid-19-influenza-combination 2024-11-11T23:27:07+00:00 weekly 0.7 https://trial.medpath.com/news/bostongene-sweeps-2024-pharmaceutical-excellence-awards-with-ai-powered-cancer-diagnostics-platform 2024-11-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/value-of-abbvie-s-cerevel-buy-uncertain-after-schizophrenia-failure-citeline 2024-11-11T22:52:05+00:00 weekly 0.7 https://trial.medpath.com/news/nk-cell-therapy-clinical-trial-pipeline-appears-robust-with-140-key-pharma-pr-newswire 2024-11-11T22:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/on-wall-street-flat-out-failure-of-abbvie-schizophrenia-drug-leaves-analysts-stunned 2024-11-11T22:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/zongertinib-a-promising-new-tki-for-her2-mutated-nsclc-pharmacy-times 2024-11-11T22:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T22:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/eureka-therapeutics-tackling-advanced-hepatocellular-carcinoma-with-t-cell-therapy 2024-11-11T22:14:12+00:00 weekly 0.7 https://trial.medpath.com/news/aberdeen-woman-says-blood-cancer-drug-approval-could-give-her-chance-of-more-normal-life 2024-11-11T22:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-cable-lock-distribution-on-firearm-securement-after-emergent-mental-health-evaluation 2024-11-11T21:48:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-nipocalimab-second-breakthrough-therapy-designation-investing-com 2024-11-11T21:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-morningstar 2024-11-11T21:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/adding-targeted-agent-to-perioperative-therapy-for-rcc-may-improve-disease-control 2024-11-11T21:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/sonoma-pharma-secures-fda-clearance-for-enhanced-wound-care-hydrogel-technology 2024-11-11T21:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/mineralys-therapeutics-reports-third-quarter-2024-financial-results-and-provides 2024-11-11T21:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/quince-therapeutics-presents-safety-data-from-prior-phase-3-attest-clinical-trial-at-53rd 2024-11-11T21:21:25+00:00 weekly 0.7 https://trial.medpath.com/news/quince-therapeutics-erydex-shows-promising-safety-data-in-phase-3-a-t-trial-qncx-stock-news 2024-11-11T21:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/livanova-announces-osprey-clinical-study-meets-primary-safety-and-efficacy-endpoints 2024-11-11T21:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough 2024-11-11T21:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/thio-combo-shows-enduring-activity-in-advanced-non-small-cell-lung-cancer 2024-11-11T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-immunotherapy-for-aggressive-leukemia-webmd 2024-11-11T21:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/major-immunotherapy-trial-sees-survival-benefit-in-solid-tumours 2024-11-11T20:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/is-rapamycin-the-next-big-breakthrough-in-periodontitis-and-oral-cancer-treatment 2024-11-11T20:49:56+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-tislelizumab-with-four-cycles-of-neoadjuvant-chemotherapy-for-resectable 2024-11-11T20:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/sngx-phase-3-ctcl-trial-to-initiate-before-end-of-2024-zacks-small-cap-research 2024-11-11T20:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-fda-approval-of-daratumumab-for-smoldering-multiple-myeloma 2024-11-11T20:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/aaopt-2024-running-the-numbers-on-ophthalmic-clinical-trials-optometry-times 2024-11-11T20:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/dosing-of-first-patient-in-a-trial-for-lsalt-peptide-is-sending-shares-higher 2024-11-11T20:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-eyes-june-fda-verdict-for-hyperphosphataemia-drug-pharmaphorum 2024-11-11T19:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-use-microcellular-drones-to-deliver-lung-cancer-killing-drugs 2024-11-11T19:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/largest-t-cell-clinical-trial-in-solid-tumors-explores-potential-for-precision-immunotherapy 2024-11-11T19:19:53+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-reports-positive-interim-efficacy-data-from-first-four-low-dose-pediatric-participants-in-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-11T19:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-emraclidine-fails-to-reduce-schizophrenia-symptoms-compared-to-placebo 2024-11-11T18:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for-stockhouse 2024-11-11T18:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-combined-administration-of-baekhogainsam-tang-and-low-dose-pilocarpine-on 2024-11-11T18:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-drug-expected-to-rival-bristol-myers-s-new-schizophrenia-med-flunks-phase-2-test 2024-11-11T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/multifunctional-antibody-shows-promise-for-treating-several-types-of-cancer-medical-xpress 2024-11-11T18:24:59+00:00 weekly 0.7 https://trial.medpath.com/news/early-serum-il-2-levels-are-associated-with-car-t-cell-expansion-post-car-t-cell-therapy 2024-11-11T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-selective-bcl-2-inhibitor-with-improved-efficacy-against-known-treatment-resistant-mutants 2024-11-11T18:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-gets-fda-approval-to-resume-testing-two-vaccines-after-clinical-hold 2024-11-11T18:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first 2024-11-11T17:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-company-adipopharma-secures-funding-to-globenewswire 2024-11-11T17:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/herbal-placebo-response-in-clinical-trials-on-irritable-bowel-syndrome-a-systematic-review 2024-11-11T17:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-stock-sinks-after-schizophrenia-drug-trials-disappoint-investopedia 2024-11-11T17:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-car-t-competitor-to-gilead-s-tecartus-biopharma-dive 2024-11-11T17:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-pause-on-novavax-flu-vaccine-trials-biopharma-dive 2024-11-11T17:16:27+00:00 weekly 0.7 https://trial.medpath.com/news/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T17:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-delays-priority-review-of-neurotech-s-eye-cell-therapy-implant 2024-11-11T17:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/based-on-recent-fda-feedback-rapt-therapeutics-stops-zelnecirnon-program-following 2024-11-11T17:11:39+00:00 weekly 0.7 https://trial.medpath.com/news/lumateperone-demonstrates-positive-efficacy-for-schizophrenia-relapse-prevention 2024-11-11T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/an-overlook-of-cagrilintinide-and-semaglutide-as-it-progresses-through-phase-3-trials 2024-11-11T17:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-adults-with-relapsed-or-refractory-b-cell 2024-11-11T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-9b-bet-collapses-as-closely-watched-schizophrenia-drug-fails-studies 2024-11-11T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-secures-fda-approval-for-car-t-cell-therapy-use-in-all 2024-11-11T16:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/citius-phase-1-trial-shows-27-response-rate-with-lymphir-keytruda-combo-in-cancer-study 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-study-combined-rna-dna-testing-boosts-lung-cancer-detection-by-15-3 2024-11-11T16:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-biotech-advances-phase-3-trial-as-q3-shows-mixed-financial-results-mbrx-stock-news 2024-11-11T16:46:37+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T16:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-shares-tumble-by-48-after-zelnecirnon-programme-cull 2024-11-11T16:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-and-merck-report-successful-phase-2-results-for-investigational-once-weekly-hiv-treatment 2024-11-11T16:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-s-ide034-breakthrough-first-in-class-cancer-drug-shows-dual-target-promise 2024-11-11T16:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-vancomycin-therapeutic-drug-monitoring-on-mortality-in-sepsis-patients-across 2024-11-11T16:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-shares-plummet-12-as-cerevel-schizophrenia-asset-fails-phase-ii-trials 2024-11-11T16:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-secures-200m-financing-to-support-trials 2024-11-11T16:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial 2024-11-11T16:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-stock-tumbles-on-failed-schizophrenia-drug-studies-bristol-myers-jumps 2024-11-11T16:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/advantage-bms-as-abbvie-drug-fails-schizophrenia-trials-pharmaphorum 2024-11-11T16:06:54+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-survival-outcomes-in-mcspc-comparison-of-apalutamide-and-abiraterone 2024-11-11T16:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/intratracheal-budesonide-mixed-with-surfactant-for-extremely-preterm-infants-jama-network 2024-11-11T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-sheds-38bn-in-value-after-failing-schizophrenia-drug-trials-nyse-abbv 2024-11-11T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/aaopt-2024-preserving-vision-by-detecting-and-treating-ga 2024-11-11T15:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in 2024-11-11T15:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-tipranks-com 2024-11-11T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-ein-presswire 2024-11-11T15:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-phase-1-trial-of-bl-m17d1-in-solid-tumors-targeted-oncology 2024-11-11T15:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/dana-farber-researchers-hijack-gut-bacteria-to-design-novel-form-of-cancer-immunotherapy 2024-11-11T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-launches-generic-paclitaxel-in-single-dose-vial-drug-store-news 2024-11-11T15:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/improving-precision-of-vaccine-efficacy-evaluation-using-immune-correlate-data-in-time-to 2024-11-11T15:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk 2024-11-11T15:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T15:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-disease-clinical-research-in-seven-major-markets-focuses-on-disease-modifying-agents 2024-11-11T15:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/spravato-is-just-the-beginning-in-a-new-wave-of-depression-meds-pharmavoice 2024-11-11T15:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/trial-shows-acupuncture-is-feasible-for-reducing-pain-in-the-emergency-department 2024-11-11T15:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-tumbles-after-new-schizophrenia-drug-fails-two-trials-yahoo-finance 2024-11-11T15:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-and-sglt2-drugs-may-help-prevent-second-strokes-and-heart-attacks-in-stroke-survivors 2024-11-11T15:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-approaches-to-gynecologic-cancer-prognosis-fueled-by-metabolomics 2024-11-11T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/uk-mhra-at-least-half-of-novel-drug-filings-to-take-national-assessment-route 2024-11-11T14:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/citius-lymphir-shows-potential-to-boost-pembrolizumab-efficacy-contract-pharma 2024-11-11T14:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/emraclidine-for-schizophrenia-fails-to-meet-primary-endpoints-in-phase-2-empower-trials 2024-11-11T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-crashes-after-axing-atopic-dermatitis-asthma-hopeful-cites-liver-injury-biospace 2024-11-11T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/ema-benefits-from-astrazeneca-significantly-outweigh-side-effects-telegraph-telegraph 2024-11-11T14:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-announces-data-demonstrating-dovato-dtg-3tc-is-highly-effective-in 2024-11-11T14:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-rockets-12-after-abbvie-s-schizophrenia-drug-fails 2024-11-11T14:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/schizophrenia-drug-abbvie-picked-up-in-9-billion-acquisition-fails-in-key-trials-stat-news 2024-11-11T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-shares-slip-after-schizophrenia-drug-trial-misses-primary-endpoint-yahoo-finance 2024-11-11T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/review-of-fda-approved-jak-inhibitors-for-alopecia-areata-hcplive 2024-11-11T14:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/how-pharmacists-can-make-an-impact-when-treating-dedifferentiated-liposarcoma-with 2024-11-11T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-s-sulopenem-receives-fda-approval-for-treatment-of-uncomplicated-urinary-tract-infections 2024-11-11T14:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-application-seeking-approval-of-darzalex-faspro-in-smoldering-myeloma 2024-11-11T14:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/resq-pharma-receives-pdufa-date-for-lipidrescuetm-as-a-potential-first-ever-fda 2024-11-11T13:57:02+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-pr-newswire 2024-11-11T13:50:47+00:00 weekly 0.7 https://trial.medpath.com/news/inflammatix-initiates-triveritytm-for-improved-management-of-emergency-department 2024-11-11T13:48:52+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in 2024-11-11T13:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/your-health-blood-test-breakthrough-revolutionizing-postpartum-depression-wafb 2024-11-11T13:41:12+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/tivozanib-monotherapy-outperforms-combination-therapy-in-post-ici-rcc-nature 2024-11-11T13:35:30+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-q3-earnings-report-puts-phase-ii-results-in-focus-nasdaq-ntla 2024-11-11T13:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combination-and-stand 2024-11-11T13:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-says-fda-accepts-nda-for-oxylanthanum-carbonate-to-treat-patients-with-ckd 2024-11-11T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/kills-ovarian-cancer-without-toxicity-in-key-study-cero-stock-news 2024-11-11T13:22:59+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-halts-key-drug-program-after-fda-safety-concerns-liver-injury 2024-11-11T13:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-class-bispecific-antibody-alg-apv-527-meets-important-trial-endpoints-in-phase-1 2024-11-11T13:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/cg-oncology-announces-nature-medicine-publication-of-phase-globenewswire 2024-11-11T13:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-bio-reports-third-quarter-financial-results-and-provides-business-update 2024-11-11T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-amgen-s-tezspire-shows-promise-in-phase-3-crswnp-trial-pmlive 2024-11-11T13:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-autolus-aucatzyl-to-treat-acute-lymphoblastic-leukaemia-pmlive 2024-11-11T13:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/scottish-medicines-consortium-approves-car-t-cell-therapy-for-blood-cancer 2024-11-11T13:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/improving-alzheimer-diagnosis-with-innovative-blood-based-biomarker-tests-and-bd-tau 2024-11-11T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/nammi-therapeutics-doses-first-subject-in-trial-of-qxl138am-for-multiple-myeloma 2024-11-11T13:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-announces-irb-approval-for-sjogren-s-syndrome-clinical-study-at-shuang-ho 2024-11-11T13:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-reaches-key-milestone-with-enrollment-of-the-first-patient-in-fpi-markets-data 2024-11-11T13:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-study-of-isatuximab-monotherapy-in-chinese-patients-with-relapsed-refractory 2024-11-11T13:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-advances-sjogren-s-treatment-key-trial-for-veldona-r-gets-irb-green-light 2024-11-11T13:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-bio-gets-fda-nod-for-phase-3-alzheimer-s-trial-cuts-losses-40-in-q3-anvs-stock-news 2024-11-11T13:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/chimerix-announces-updated-phase-2-response-assessment-of-dordaviprone-in-morningstar 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T13:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-enrolment-in-pulsed-field-ablation-trial-clinical-trials-arena 2024-11-11T13:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-research-finds-that-alzheimer-s-can-be-transmitted-between-people 2024-11-11T12:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-receives-usfda-final-approval-for-diltiazem-hydrochloride-er-capsules 2024-11-11T12:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-yahoo-finance 2024-11-11T12:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-dosing-of-first-patient-in-canada-in-the-phase-ii-trial-for 2024-11-11T12:35:17+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-initiation-of-phase-1-clinical-study-of-ck-4015089-stock-titan 2024-11-11T12:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-dosing-of-first-patient-in-globenewswire 2024-11-11T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/gastric-cancer-awareness-month-2024-looking-back-at-progress-for-cell-therapy-cgtlive-r 2024-11-11T12:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/ethics-approval-received-in-indonesia-to-commence-dosing-in-a-registrational-phase-3 2024-11-11T12:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-amgen-claim-late-stage-win-in-chronic-rhinosinusitis-but-analyst-flags 2024-11-11T12:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-launches-phase-iia-trial-for-fda-designated-orphan-drug-in-pancreatic-cancer 2024-11-11T12:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/chimerix-cancer-drug-shows-28-response-rate-in-phase-2-brain-tumor-trial-cmrx-stock-news 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-mirdametinib-data-to-be-presented-at-the-2024-stock-titan 2024-11-11T12:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-11T12:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/momentis-surgical-receives-fda-510-k-clearance-for-second-generation-anovo-r-robotic 2024-11-11T12:05:52+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-globenewswire 2024-11-11T12:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-iia-clinical-trial 2024-11-11T12:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-s-kidney-disease-drug-gets-fda-review-date-aims-for-2025-launch-uncy-stock-news 2024-11-11T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/australian-german-research-finds-world-first-cure-for-deadly-skin-disease-daijiworld-com 2024-11-11T11:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/paratek-s-antibiotic-succeeds-in-phase-iib-lung-disease-trial 2024-11-11T11:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-publication-of-the-pivotal-phase-2b-reneu-trial 2024-11-11T11:33:23+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-development-candidate-nomination-of-ide034-a-potential-first-in 2024-11-11T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharmaceuticals-gains-us-fda-approval-for-diltiazem-capsules-to-treat-hypertension 2024-11-11T11:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/biocytogen-announces-ideaya-s-nomination-of-development-candidate-ide034-a-via-ritzau 2024-11-11T11:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-limited-market-designation-to-vivesto-s-paccal-vet-marketscreener 2024-11-11T11:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-bags-health-canada-nod-for-rsv-vaccine-for-adults-aged-60-years-and-older 2024-11-11T11:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/patient-with-sickle-cell-disease-dies-from-complications-related-to-busulfan-conditioning 2024-11-11T11:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-meds-help-stroke-survivors-prevent-stroke-recurrence-death 2024-11-11T11:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/hourglass-shaped-stent-might-ease-tough-to-treat-angina 2024-11-11T11:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/trbc1-car-t-cell-therapy-in-peripheral-t-cell-lymphoma-a-phase-1-2-trial-nature 2024-11-11T10:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/vivesto-s-paccal-vet-receives-limited-market-classification-in-eu-tradingview-news 2024-11-11T10:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-receives-usfda-approval-for-hypertension-drug-equitypandit 2024-11-11T10:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-mresvia-vaccine-gains-health-canada-approval-pharmaceutical-technology 2024-11-11T10:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-marketscreener 2024-11-11T10:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-morningstar 2024-11-11T10:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/data-fomo-may-undermine-clinical-trials-roi-phesi-warns-laboratory-news 2024-11-11T10:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/tectonic-therapeutic-announces-positive-phase-1a-results-in-globenewswire 2024-11-11T10:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/palleon-pharmaceuticals-reports-phase-i-ii-trial-results-of-e-602-for-solid-tumours 2024-11-11T09:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharmaceuticals-gets-usfda-nod-for-generic-hypertension-treatment-capsules 2024-11-11T09:42:36+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-bags-fda-approval-for-leukaemia-cell-therapy-pharmaphorum 2024-11-11T09:35:20+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharmaceuticals-gains-usfda-final-approval-for-diltiazem-hydrochloride-extended 2024-11-11T09:33:59+00:00 weekly 0.7 https://trial.medpath.com/news/will-adlai-be-the-first-to-deliver-a-pi3k-inhibitor-for-head-and-neck-squamous-cell-carcinoma 2024-11-11T09:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-killing-virus-shows-promise-against-aggressive-brain-tumors 2024-11-11T09:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-reports-business-pipeline-and-financial-update-for-q3-2024-pharmiweb-com 2024-11-11T09:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/research-suggests-no-need-for-yellow-fever-vaccine-booster-after-initial-dose 2024-11-11T09:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/shandong-xinhua-pharma-secures-key-drug-approval-tipranks-com 2024-11-11T09:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-provides-business-update-with-third-quarter-2024-financial-results-biospace 2024-11-11T09:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/trump-s-healthcare-agenda-raises-concerns-rfk-jr-s-potential-role-and-aca-s-future-in-focus 2024-11-11T09:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-menafn 2024-11-11T09:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib-pharmaceutical-technology 2024-11-11T09:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T09:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/australia-and-uk-team-up-to-fund-clinical-trials-research-professional-news 2024-11-11T08:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/sweden-cereno-scientific-secures-financial-runway-into-2026-investors-in-healthcare 2024-11-11T08:55:20+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-doses-first-patient-in-hard-to-treat-cancer-drug-trial-the-west-australian 2024-11-11T08:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-gets-fda-approval-for-leukaemia-treatment-sharecast-com 2024-11-11T08:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-finally-ban-controversial-ingredient-in-popular-decongestants-sciencealert 2024-11-11T08:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/investment-surges-hurdles-and-emerging-innovations-in-neuroscience-yahoo 2024-11-11T08:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-pr-newswire 2024-11-11T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/enterobiotix-announces-positive-ph1b-clinical-results-of-ebx-102-in-liver-cirrhosis 2024-11-11T08:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/luye-pharma-gains-approval-for-innovative-antidepressant-trials-markets-insider 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T07:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/largest-t-cell-clinical-trial-in-solid-tumors-heralds-new-era-in-precision-immunotherapy 2024-11-11T07:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/gamma-delta-t-cells-emerge-as-promising-alternative-to-car-t-for-solid-tumors-and-autoimmune-diseases 2024-11-11T07:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-gets-usfda-approval-hypertension-drug-india-infoline 2024-11-11T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:20:56+00:00 weekly 0.7 https://trial.medpath.com/news/oncoinvent-announces-promising-interim-results-for-radspherin-r-as-a-potential-treatment 2024-11-11T07:20:41+00:00 weekly 0.7 https://trial.medpath.com/news/angle-plc-announces-parsortix-enriched-ctc-ctdna-in-nsclc-patients-stock-titan 2024-11-11T07:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-gains-fda-approval-for-leukemia-therapy-tipranks-com 2024-11-11T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-secures-funding-for-clinical-trials-tipranks-com 2024-11-11T07:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/cereno-scientific-secures-sek-250-million-in-debt-financing-marketscreener 2024-11-11T07:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-receives-us-fda-approval-company-announcement-investegate 2024-11-11T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/investment-surges-hurdles-and-emerging-innovations-in-neuroscience 2024-11-11T07:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-testing-revolutionizes-treatment-approaches-in-diffuse-large-b-cell-lymphoma 2024-11-11T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-biospace 2024-11-11T06:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/relief-therapeutics-eb-treatment-shows-78-wound-closure-rate-in-breakthrough-trial 2024-11-11T06:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/curasight-announces-brain-cancer-as-first-indication-for-utreat-r-first-patient-to-be-dosed 2024-11-11T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/japan-recommends-approval-of-brukinza-balversa-citeline 2024-11-11T06:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-industry-adapts-to-evolving-challenges-ai-and-innovation-key-to-clinical-trial-success 2024-11-11T06:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-cardiovascular-and-renal-outcomes-of-liraglutide-versus-dulaglutide-in-asian 2024-11-11T06:28:30+00:00 weekly 0.7 https://trial.medpath.com/news/major-t-cell-trial-in-solid-tumors-marks-new-era-mirage-news 2024-11-11T06:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-gets-usfda-nod-for-hypertension-treatment-drug-cnbc-tv18 2024-11-11T05:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-us-eu-approvals-for-darzalex-faspro-darzalex-as-pharmabiz-com 2024-11-11T05:31:18+00:00 weekly 0.7 https://trial.medpath.com/news/5-huntington-s-therapies-to-watch-biospace 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-of-failure-first-disease-modifying-huntington-s-treatment-on-the-horizon 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-study-reveals-strong-links-between-hidradenitis-suppurativa-and-cardiometabolic-diseases 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-heart-valve-device-at-musc-offers-safer-treatment-for-tricuspid-regurgitation 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pe-cgs-network-advances-patient-partnered-cancer-research-despite-implementation-challenges 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-and-nucleus-radiopharma-scale-up-manufacturing-for-cancer-treatment 2024-11-11T04:50:53+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-tentative-u-s-fda-approval-for-raltegravir-tablets-express-pharma 2024-11-11T04:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents-says-globaldata 2024-11-11T04:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/quick-listen-scrip-s-five-must-know-things-citeline 2024-11-11T04:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-kenyans-as-kemri-recommends-new-hiv-prevention-drugs-tv47-digital 2024-11-11T04:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-expands-car-t-cell-and-oncolytic-virotherapy-trials-in-australia-and-the-us 2024-11-11T04:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/while-the-orphan-battles-wage-jazz-takes-a-loss-food-and-drugs-law-mondaq 2024-11-11T03:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-astrazeneca-s-enhertu-receives-2024-prix-galien-usa-award-for-best 2024-11-11T03:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-11T03:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presents-the-latest-clinical-data-of-anti-her2-bispecific-adc 2024-11-11T03:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-new-drug-application-nda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-11-11T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-markets-insider 2024-11-11T03:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaking-abstract-alphamab-oncology-presented-the-latest-clinical-data-of-anti 2024-11-11T02:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease 2024-11-11T02:11:39+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T02:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/sino-biopharm-s-garsorasib-gains-approval-in-china-markets-insider 2024-11-11T02:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program 2024-11-11T01:38:19+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-garners-ethics-approval-for-anti-infective-phase-3-clinical-trial-in-indonesia 2024-11-11T01:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/australia-s-clarity-pharma-jumps-on-deal-with-us-co-tradingview 2024-11-11T01:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/could-everyday-plastics-be-impacting-your-fertility-newcastle-hmri 2024-11-11T00:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/ai-vs-humans-are-ai-chatbots-ready-for-real-mental-health-conversations-hmri 2024-11-11T00:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/ai-algorithm-achieves-80-precision-in-detecting-long-covid-through-electronic-health-records 2024-11-11T00:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-is-working-on-breast-cancer-vaccines-firstcoastnews-com 2024-11-11T00:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-shows-effectiveness-of-nanoparticles-in-diagnosing-treating-plaque-in-arteries 2024-11-11T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-holding-promising-pipeline-and-market-potential-support-buy-rating 2024-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-biotech-stocks-on-the-move-in-october-claire-aitchison-livewire-markets 2024-11-10T23:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-tipranks-com 2024-11-10T23:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/naspghan-2024-pedfic-data-highlight-safety-of-odevixibat-in-pediatric-patients-with-pfic 2024-11-10T23:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/participants-needed-for-clinical-trials-for-norovirus-nevada-appeal 2024-11-10T23:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/digital-health-funding-roundup-aignostics-secures-34m-series-b-for-ai-powered-pathology-platform 2024-11-10T23:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-cure-for-lethal-skin-disease-achieved-in-landmark-study-wehi 2024-11-10T22:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-modelling-progressive-ms-in-the-lab-reveals-how-cholesterol-can-damage-nerves 2024-11-10T22:50:42+00:00 weekly 0.7 https://trial.medpath.com/news/roflumilast-cream-0-15-addresses-unmet-needs-of-adults-children-with-atopic-dermatitis 2024-11-10T21:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-for-autoimmune-disease-treatment 2024-11-10T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-wants-to-pull-decongestant-found-in-many-cold-allergy-medicines-fox-26-houston 2024-11-10T19:26:10+00:00 weekly 0.7 https://trial.medpath.com/news/intas-pharmaceuticals-gets-cdsco-panel-nod-to-study-r-hfsh-solution-for-injection 2024-11-10T18:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/virus-therapy-gets-orphan-drug-designation-for-glioma-treatment-oncology-nursing-news 2024-11-10T18:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/serial-killing-cell-therapy-from-autolus-lands-fda-approval-in-blood-cancer 2024-11-10T17:32:45+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-bids-to-add-smouldering-myeloma-to-darzalex-label-pharmaphorum 2024-11-10T17:28:14+00:00 weekly 0.7 https://trial.medpath.com/news/antio-cel-shows-promising-results-in-relapsed-refractory-multiple-myeloma 2024-11-10T17:12:43+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-pill-passes-important-safety-trial-new-atlas 2024-11-10T16:43:40+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-relmada-therapeutics-reports-q3-financials-focuses-on-rel-1017 2024-11-10T16:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/nktr-255-shows-promise-for-reversing-radiation-induced-lymphopenia-in-nsclc 2024-11-10T16:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-assess-the-role-of-vitamin-k2-in-managing-nocturnal-leg-cramps 2024-11-10T15:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-10T14:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-trial-raises-concerns-for-accelerating-cognitive-decline-new-atlas 2024-11-10T14:26:11+00:00 weekly 0.7 https://trial.medpath.com/news/harbinger-health-to-speed-up-clinical-cancer-test-validation-european-biotechnology 2024-11-10T14:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-s-promising-trial-results-bolster-prospects-markets-insider 2024-11-10T13:56:34+00:00 weekly 0.7 https://trial.medpath.com/news/establishment-and-characterization-of-mouse-metabolic-dysfunction-associated-nature 2024-11-10T12:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol 2024-11-10T12:45:04+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-discovery-links-manuka-honey-to-breast-cancer-treatment-evrim-agaci 2024-11-10T12:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/elan-investor-update-did-elanco-animal-health-mislead-globenewswire 2024-11-10T12:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-self-collection-hpv-tests-as-an-alternative-to-pap-smears-columbia-missourian 2024-11-10T12:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-a-review-of-last-month-s-fda-prominent-actions-and-key-data 2024-11-10T12:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/what-prevents-fda-approval-of-sublingual-immunotherapy-new-york-city-ny-patch 2024-11-10T11:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/jnj-seeks-approval-from-usfda-ema-for-darzalex-faspro-as-subcutaneous 2024-11-10T10:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/hyperbaric-oxygen-therapy-for-combat-associated-ptsd-psychiatrist-com 2024-11-10T10:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/water-bead-injuries-in-children-show-alarming-rise-national-study-reports-9-requiring-escalated-care 2024-11-10T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-s-rp1-shows-33-6-response-rate-in-melanoma-trial-marks-breakthrough-stock-titan 2024-11-10T09:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-delcath-systems-q3-2024-results-show-robust-growth-investing-com 2024-11-10T09:24:07+00:00 weekly 0.7 https://trial.medpath.com/news/after-germany-france-and-italy-suspend-the-astrazeneca-vaccine-of-covid-19-telegrafi 2024-11-10T07:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/erythropoietin-exposure-in-neonates-with-hypoxic-ischemic-encephalopathy-in-the-heal-trial 2024-11-10T07:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/early-smoking-cessation-treatment-after-cancer-diagnosis-significantly-boosts-survival-rates 2024-11-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-to 2024-11-10T06:56:54+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-highlights-cancer-selective-her2-targeting-profile-of-ft825-ono 2024-11-10T06:47:10+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-10T06:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-ocugen-outlines-progress-in-ophthalmology-trials-financials-investing-com 2024-11-10T05:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-strong-link-between-undiagnosed-asthma-and-insomnia-risk 2024-11-10T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncoresponse-announces-phase-1-results-of-the-clinical-trial-of-or502-anti-lilrb2 2024-11-10T04:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-potential-of-neuroimmune-modulation-in-treatment-paradigm-of-relapsing 2024-11-10T04:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/hong-kong-approves-celebrity-weight-loss-drug-but-experts-say-it-s-not-just-to-look-good 2024-11-10T04:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/ama-debates-physician-compensation-for-prior-authorization-work-at-interim-meeting 2024-11-10T03:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-cancer-treatment-paradigm-shifts-with-enfortumab-vedotin-pembrolizumab-combination-expert-highlights-at-sylvester-oncology-update 2024-11-10T03:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/day-3-recap-elevate-derm-west-2024-dermatology-times 2024-11-10T02:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T02:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/lower-pharmacy-costs-give-ruxolitinib-edge-for-patients-with-mf-and-anemia 2024-11-10T01:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-sitc-2024-special-edition 2024-11-10T01:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/another-signal-of-concern-with-abacavir-and-cardiovascular-risk-catie-ca 2024-11-10T00:53:50+00:00 weekly 0.7 https://trial.medpath.com/news/lauren-collen-md-advanced-combination-therapy-may-be-effective-option-for-pediatric 2024-11-10T00:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T00:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-begins-phase-3-trial-for-microcystic-lymphatic-malformations-treatment 2024-11-10T00:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-corneal-transplants-using-human-ips-cells-restores-vision-gurufocus 2024-11-10T00:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/cab-gel-shows-promising-results-for-hispanic-patients-with-acne-dermatology-times 2024-11-10T00:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/tarlatamab-dlle-for-previously-treated-extensive-stage-sclc 2024-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-medical-s-prosense-system-gains-favorable-fda-panel-recommendation-and 2024-11-09T23:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/post-hoc-analysis-reveals-potential-serum-glycoproteomic-biomarkers-for-nivolumab-onclive 2024-11-09T23:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-for-kidney-cancer-builds-on-efficacy-record-medpage-today 2024-11-09T22:57:19+00:00 weekly 0.7 https://trial.medpath.com/news/as-ai-transforms-drug-development-fda-is-scrambling-to-figure-out-guardrails-law-com 2024-11-09T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-proposes-ban-on-over-the-counter-decongestant-nevada-globe 2024-11-09T22:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-09T22:27:11+00:00 weekly 0.7 https://trial.medpath.com/news/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/benralizumab-effectiveness-in-patients-with-severe-eosinophilic-asthm-jaa-dove-medical-press 2024-11-09T22:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/novel-bladder-cancer-treatment-gains-mhra-approval-in-the-uk-news-medical 2024-11-09T22:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-highlights-cancer-selective-globenewswire 2024-11-09T21:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-biotechnologies-get-expanded-medicare-coverage-of-clonoseq-for-pharmabiz-com 2024-11-09T21:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-november-4-2024 2024-11-09T21:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-allogene-therapeutics-reports-on-car-t-therapy-progress-by-investing-com 2024-11-09T21:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/details-surrounding-phase-3-study-of-ion582-in-angelman-syndrome-announced 2024-11-09T20:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/delta-2-trial-shows-delgocitinib-cream-safe-with-minimal-systemic-absorption-for-chronic 2024-11-09T20:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/japanese-researchers-discover-drug-that-regenerates-teeth-in-just-6-years-union-rayo 2024-11-09T19:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-receives-us-fda-rare-paediatric-disease-orphan-drug-designations-for-ab-1003-to 2024-11-09T19:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world 2024-11-09T19:18:28+00:00 weekly 0.7 https://trial.medpath.com/news/aprea-therapeutics-reports-q3-financials-and-advances-in-clinical-trials-mychesco 2024-11-09T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/vistagen-therapeutics-promising-clinical-progress-and-strong-financial-position-justify-buy-rating 2024-11-09T19:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/good-news-this-week-november-9-2024-dogs-ferrets-woodpeckers 2024-11-09T19:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-announces-new-data-highlighting-globenewswire 2024-11-09T18:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/team-at-mayo-clinic-in-arizona-completes-first-larynx-transplant 2024-11-09T18:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-09T18:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-09T18:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-pharmaceutical-inc-presents-positive-update-on-gtx-102-angelman-syndrome 2024-11-09T18:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-to-present-long-term-efficacy-and-safety-data-from-phase-3-defi-trial-of-ogsiveo 2024-11-09T18:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of-rp1 2024-11-09T18:17:42+00:00 weekly 0.7 https://trial.medpath.com/news/linaclotide-effective-for-functional-constipation-in-children-with-neurodevelopmental-disorders 2024-11-09T18:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-09T18:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/views-everyone-must-do-more-to-take-care-of-veterans-shaw-local 2024-11-09T18:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-rimegepant-medical-dialogues 2024-11-09T17:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/hold-recommendation-for-vir-biotechnology-amid-cautious-optimism-on-infectious-disease 2024-11-09T17:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/a1c-drink-inc-announces-start-of-clinical-trials-in-early-2025-targeting-a-breakthrough-in 2024-11-09T16:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/ga-therapies-coming-down-the-pike-modern-retina 2024-11-09T16:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytic-immunotherapy-with-nivolumab-in-muscle-invasive-bladder-cancer-a-phase-1b-trial 2024-11-09T16:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/study-documents-detrimental-effects-of-drug-shortages-in-this-case-etoposide 2024-11-09T16:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-hr-chief-pamela-cramer-sells-585940-in-stock-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-arcturus-therapeutics-reported-a-net-loss-of-6-9-million-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/next-steps-for-cilta-cel-and-cartitude-4-in-multiple-myeloma-targeted-oncology 2024-11-09T16:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program-at-fast-s 2024-11-09T15:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-globenewswire 2024-11-09T15:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/promising-os-at-5-years-with-chemo-free-combo-in-urothelial-cancer-medpage-today 2024-11-09T15:31:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mi-cancer-seek-as-companion-diagnostic-for-adult-and-pediatric-patients 2024-11-09T15:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value-cnbc 2024-11-09T14:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/indapta-therapeutics-presents-clinical-and-preclinical-data-of-allogenic-natural-killer-cell 2024-11-09T14:51:52+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-09T14:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/urgent-ozempic-and-wegovy-warning-as-10-deaths-linked-to-weight-loss-jabs-the-mirror 2024-11-09T14:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/red-flag-symptoms-of-condition-affecting-69000-women-as-hopes-grow-of-cure-surrey-live 2024-11-09T14:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/global-study-reveals-stark-disparities-in-biologic-access-for-atopic-dermatitis-treatment-across-50-countries 2024-11-09T14:00:16+00:00 weekly 0.7 https://trial.medpath.com/news/allovir-sees-a-new-direction-with-kalaris-merger-bioworld 2024-11-09T13:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-therapy-approved-for-leukemia-medpage-today 2024-11-09T13:39:29+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approval-for-moderna-s-rsv-vaccine-biotechnology-the-pharmaletter 2024-11-09T13:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-3-onclive 2024-11-09T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-places-hold-on-rap-219-cappricorn-1-study-to-assess-mivelsiran-in-caa-fda 2024-11-09T12:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-seeks-us-fda-approval-for-sunvozertinib-to-treat-relapsed-or-refractory-nsclc-with 2024-11-09T11:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/subgroup-analyses-give-weight-for-next-level-trial-of-gv1001-in-progressive-supranuclear-palsy 2024-11-09T11:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/exclusive-clinical-trials-to-assess-health-benefits-of-ricky-kej-s-grammy-nominated 2024-11-09T11:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/rising-revenue-strategic-pipeline-advances-propel-biotech-growth-trajectory 2024-11-09T10:58:14+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-tentative-approval-from-usfda-for-raltegravir-tablets-indian-pharma-post 2024-11-09T10:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-tapinarof-cream-1-timeline-menacwy-vaccination-program-and-more 2024-11-09T10:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/2-new-studies-highlight-issues-with-treatment-of-anaphylaxis-hcplive 2024-11-09T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/cleveland-clinic-presents-new-findings-on-triple-negative-breast-cancer-vaccine 2024-11-09T09:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-puma-biotechnology-reports-robust-q3-growth-investing-com 2024-11-09T09:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/entera-bio-reports-q3-2024-financial-results-and-provides-business-updates 2024-11-09T09:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/aptose-reports-results-for-the-third-quarter-2024-globenewswire 2024-11-09T09:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-drug-shortages-hit-decade-high-with-323-active-cases-ashp-reports 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-providers-strongly-support-lowering-pneumococcal-vaccine-age-recommendation-to-50-years 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-clinical-trial-for-integrated-single-device-to-treat-pad-daic 2024-11-09T08:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/at-fortune-global-forum-2024-alex-zhavoronko-eurekalert 2024-11-09T08:50:49+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-current-use-and-future-of-alternatives-to-traditional-informed-consent-in-acute 2024-11-09T08:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/thio-plus-cemiplimab-displays-efficacy-in-checkpoint-inhibitor-resistant-nsclc 2024-11-09T08:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-nec-to-present-new-data-confirming-clinical-proof-of-principle-for-neoantigen 2024-11-09T08:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-evaluate-the-safety-and-efficacy-of-brivudine-as-oral-shingles-treatment 2024-11-09T08:25:37+00:00 weekly 0.7 https://trial.medpath.com/news/cd47-levels-are-prognostic-of-response-to-magrolimab-plus-docetaxel-in-metastatic-nsclc 2024-11-09T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/news/combining-lutetium-psma-with-hormonal-therapy-enhances-prostate-cancer-treatment 2024-11-09T08:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-vibostolimab-pembrolizumab-plus-chemo-meets-futility-threshold-in-es-sclc 2024-11-09T08:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-reports-q3-2024-results-amid-fda-review-markets-insider 2024-11-09T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-8-2024 2024-11-09T08:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/pd-l1-kim-1-expression-are-predictive-of-outcomes-with-adjuvant-nivolumab-alone-plus 2024-11-09T07:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-wins-fda-approval-of-aucatzyl-for-acute-lymphoblastic-leukemia-seeking-alpha 2024-11-09T07:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-balversa-gains-mhra-marketing-authorization-as-monotherapy-for-bladder-cancer 2024-11-09T06:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-here-s-why 2024-11-09T06:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-renews-reduced-risk-authorization-for-eight-swedish-match-products 2024-11-09T06:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-evaluation-of-a-novel-hemostatic-gelatin-matrix-for-intraoperative-hemostasis 2024-11-09T06:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/trontinemab-data-strengthen-hope-for-brain-shuttles-alzforum 2024-11-09T06:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-for-shanghai-henlius-biotech-s-and-organon-s-hlx14-a-denosumab-biosimilar 2024-11-09T05:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-study-of-pulse-field-ablation-as-first-line-afib-therapy 2024-11-09T05:35:15+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-positioned-for-growth-with-promising-trial-developments-and-strong-financials 2024-11-09T05:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-webwire 2024-11-09T05:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-offers-promise-for-terrible-terrible-brain-cancer-in-young-people 2024-11-09T05:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/trump-s-2024-election-victory-signals-major-shifts-in-us-healthcare-policy 2024-11-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-dimopoulos-on-efficacy-findings-from-the-dreamm-8-trial-in-multiple-myeloma 2024-11-09T04:54:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-october-approvals-include-the-first-cldn18-2-mab-biocentury 2024-11-09T04:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-multiple-sclerosis-medpage-today 2024-11-09T04:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/lurie-children-s-developing-optical-genome-mapping-test-for-brain-tumors 2024-11-09T04:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/donanemab-small-tweak-in-titration-big-gain-in-safety-alzforum 2024-11-09T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/huyabio-presents-positive-phase-2-data-on-hbi-8000-and-nivolumab-combination-for 2024-11-09T03:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024 2024-11-09T03:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/sec-recommends-approval-for-msn-laboratories-sleep-disorder-drug-pharmabiz-com 2024-11-09T02:29:50+00:00 weekly 0.7 https://trial.medpath.com/news/dostarlimab-plus-chemo-yield-strong-survival-results-in-metastatic-nsclc 2024-11-09T02:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-offers-new-hope-for-weight-loss-seekers-local-12 2024-11-09T02:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-inc-bcab-q3-2024-earnings-call-highlights-strategic-a-gurufocus 2024-11-09T01:58:49+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-ai-unveils-breakthrough-cancer-treatment-algorithm-cost-saving-study-at-sitc-2024 2024-11-09T00:47:44+00:00 weekly 0.7 https://trial.medpath.com/news/ntla-2002-gene-editing-reduces-angioedema-attacks-in-hereditary-angioedema 2024-11-09T00:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial 2024-11-09T00:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-on-alzheimer-s-disease-ctad-2023-16th-alzforum 2024-11-09T00:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-r-pembrolizumab-significantly 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-statement-on-fda-advisory-committee-meeting-for-zinplava 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-phase-iii-nasal-polyp-data-may-lead-to-second-indication-citeline 2024-11-08T23:18:30+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-gets-fda-approval-for-cancer-treatment-morningstar 2024-11-08T23:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/evolving-role-of-mrd-status-in-multiple-myeloma-the-asco-post 2024-11-08T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-adult-leukemia-treatment-healio 2024-11-08T22:59:10+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-s-amylin-obesity-drug-could-rival-novo-s-but-it-needs-a-partner-citeline 2024-11-08T22:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/3-latest-medical-breakthroughs-to-know-about-in-2024 2024-11-08T22:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-plc-tezspire-meets-primary-endpoints-in-waypoint-trial 2024-11-08T22:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obe-cel-for-adults-with-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T22:19:14+00:00 weekly 0.7 https://trial.medpath.com/news/eyeing-the-future-of-oncology-highlights-from-the-presidential-symposium-at-esmo-congress-2024 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/unexpected-results-in-solid-tumors-what-we-learned-from-negative-findings 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-aucatzyl-for-adults-with-aggressive-leukemia 2024-11-08T22:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obe-cel-for-r-r-b-cell-acute-lymphoblastic-leukemia 2024-11-08T22:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/positive-trials-continue-to-shape-the-sclc-treatment-landscape-targeted-oncology 2024-11-08T22:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-relapsed-refractory-b-cell-precursor-all 2024-11-08T22:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-renews-authorization-for-eight-general-snus-products-nacs 2024-11-08T21:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-car-t-cell-therapy-for-relapsed-or-refractory-b-cell-all-cure-today 2024-11-08T21:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-in-b-cell-all-cancer-network 2024-11-08T21:27:57+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:26:53+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-globenewswire 2024-11-08T21:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T21:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/ima203-shows-frequent-enduring-responses-and-tolerability-in-melanoma 2024-11-08T21:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-inc-sec-10-q-report-tradingview 2024-11-08T21:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-aucatzyl-obecabtagene-autoleucel-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-08T21:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-successful-phase-iii-trial-for-tezspire-marketscreener 2024-11-08T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-obe-cel-in-relapsed-refractory-b-all-targeted-oncology 2024-11-08T21:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-therapy-yields-notable-outcomes-in-triple-negative-breast-cancer 2024-11-08T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/cue-biopharma-presents-positive-updated-data-from-its-phase-1-trials-of-cue-101-biospace 2024-11-08T20:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-dostarlimab-chemo-maintains-numerical-os-benefit-in-advanced-nsclc 2024-11-08T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-for-new-indications-for-darzalex-markets-insider 2024-11-08T20:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/former-fitness-instructor-beyond-excited-to-receive-lupus-therapy-in-uk-first 2024-11-08T20:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T19:55:42+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap 2024-11-08T19:38:56+00:00 weekly 0.7 https://trial.medpath.com/news/remembering-bruce-albala-70-leader-in-bace-inhibitor-development-alzforum 2024-11-08T19:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-takes-step-toward-removal-of-ineffective-decongestants-from-the-market 2024-11-08T18:56:12+00:00 weekly 0.7 https://trial.medpath.com/news/cue-biopharma-cancer-drug-trial-soars-91-survival-rate-shatters-expectations 2024-11-08T18:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-has-mixed-q3-results-positive-eversense-365-outlook-drug-delivery-business 2024-11-08T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/cue-biopharma-presents-positive-updated-data-from-its-phase-globenewswire 2024-11-08T18:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T18:28:29+00:00 weekly 0.7 https://trial.medpath.com/news/cmn-weekly-8-november-2024-your-weekly-crispr-medicine-news 2024-11-08T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-us-fda-tentative-approval-for-raltegravir-tablets-usp-pharmabiz-com 2024-11-08T18:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-reveals-promising-phase-2-trial-results-tipranks-com 2024-11-08T18:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-nda-submitted-to-fda-for-nsclc 2024-11-08T18:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-launches-institute-for-cell-therapy-discovery-innovation-to-deliver 2024-11-08T18:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/kiora-pharmaceuticals-reports-third-quarter-results-retinal-disease-pipeline-advancing 2024-11-08T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-biomedical-life-sciences-company-raises-c-16-million-pulse-2-0 2024-11-08T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-disease-what-treatments-could-be-rolled-out-in-the-next-few-years-the-bmj 2024-11-08T17:48:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-sought-for-sunvozertinib-in-pretreated-egfr-exon-20-advanced-nsclc 2024-11-08T17:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/modified-kisunla-dosing-lowers-risk-of-aria-e-in-alzheimer-s-study 2024-11-08T17:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-updates-kva12123-clinical-results-from-ongoing-phase-1-2-vista101-study-at 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-therapeutics-reports-third-quarter-2024-financial-results-and-recent-developments 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-launches-institute-for-cell-therapy-di-newswise 2024-11-08T17:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-myeloma 2024-11-08T17:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/mb-108-gains-fda-orphan-drug-status-for-malignant-glioma-treatment 2024-11-08T17:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/hurricane-helene-delays-spectral-medical-s-confirmatory-trial-enrolment 2024-11-08T16:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-plans-to-ban-ineffective-cold-medicine-ingredient-how-it-will-affect-you-health 2024-11-08T16:52:17+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-therapeutics-hopes-to-hit-big-milestones-by-year-end 2024-11-08T16:50:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ifetroban-for-treatment-of-duchenne-muscular 2024-11-08T16:46:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-high-risk-smoldering-myeloma 2024-11-08T16:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-succeeds-in-chronic-rhinosinusitis-gilead-writes-down-trodelvy-value 2024-11-08T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/oncoresponse-reports-data-of-phase-i-solid-tumour-treatment-trial-clinical-trials-arena 2024-11-08T16:24:31+00:00 weekly 0.7 https://trial.medpath.com/news/alignment-extending-our-clinical-trials-to-more-patients-yale-school-of-medicine 2024-11-08T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T16:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/les-turner-symposium-on-als-unites-community-around-research-and-patient-care 2024-11-08T16:05:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-johnson-johnson-s-varipulse-for-drug-resistant-paroxysmal-atrial-fibrillation 2024-11-08T15:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-08T15:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-awarded-the-prix-galien-usa-2024-prize-for-best-startup-the-globe-and-mail 2024-11-08T15:40:22+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-ipilimumab-in-aggressive-thyroid-carcinoma-the-asco-post 2024-11-08T15:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-new-drug-application-in-egfr-mutant-nsclc-submitted-to-fda 2024-11-08T15:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/compass-therapeutics-reveals-breakthrough-biomarker-data-for-cancer-drug-ctx-471 2024-11-08T15:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-rosacea-treatment-proposal-to-remove-oral-phenylephrine-from-otc-products 2024-11-08T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-gastroparesis-hospitalizations-surge-post-covid-19-chop-study-reveals 2024-11-08T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-approval-of-darzalex-faspro-in-us-darzalex-in-eu-for-myeloma 2024-11-08T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-rsv-medpage-today 2024-11-08T15:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/dogwood-therapeutics-inc-sec-10-q-report-tradingview 2024-11-08T15:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T15:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/skyrizi-overtakes-humira-in-u-s-sales-numbers-managed-healthcare-executive 2024-11-08T15:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/expert-comments-on-the-risks-and-benefits-of-tirzepatide-following-the-death-of-susan-mcgowan 2024-11-08T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/uclh-announces-start-of-car-t-cell-therapy-clinical-trial-for-lupus-patients 2024-11-08T14:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets 2024-11-08T14:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-pull-common-but-ineffective-cold-medicine-from-market-cbs-news 2024-11-08T14:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/iag-beats-on-q3-revenue-astrazeneca-discloses-positive-phase-3-clinical-trial 2024-11-08T14:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/extrachromosomal-dna-spread-oncogenic-traits-add-synthetic-lethal-targets 2024-11-08T14:27:20+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine 2024-11-08T14:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-08T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-s-cancer-biomarker-test-outshines-standard-ici-predictive-tests 2024-11-08T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic-rhinosinusitis-with-nasal-polyps 2024-11-08T14:17:50+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/biostock-full-phase-ii-results-of-upar-pet-in-glioblastoma-published-cision-news 2024-11-08T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/luspatercept-improved-diagnostics-deliver-in-mds-targeted-oncology 2024-11-08T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-akin-gump 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-marketing-for-first-combination-flu-and-covid-19-at-home-test-outside-of 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-therapy-with-potential-to-transform-lupus-treatment-delivered-in-manchester-in-uk-first 2024-11-08T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-says-phase-iii-waypoint-study-of-tezspire-met-primary-goals-rttnews 2024-11-08T13:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-08T13:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/xilio-therapeutics-announces-initial-clinical-trial-data-from-phase-1c-dose-escalation-biospace 2024-11-08T13:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/immunovant-provides-development-updates-and-reports-financial-results-for-the-quarter 2024-11-08T13:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T13:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-08T13:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-medtech-receives-us-fda-approval-for-varipulse-pfa-platform-in-af-treatment 2024-11-08T13:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-j-j-s-device-for-heart-condition-healthleaders-media 2024-11-08T13:28:38+00:00 weekly 0.7 https://trial.medpath.com/news/mariposa-2-second-interim-survival-data-targeted-oncology 2024-11-08T13:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/ncats-award-to-support-multi-site-study-evaluating-remote-trials-university-at-buffalo 2024-11-08T13:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/minn-ems-looks-to-enroll-trauma-patients-in-blood-loss-drug-trials-ems1 2024-11-08T13:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seek-approval-of-darzalex 2024-11-08T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/cleveland-clinic-announces-updated-findings-in-preventive-breast-cancer-vaccine-study 2024-11-08T13:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-fda-ema-nod-for-myeloma-treatment-investing-com 2024-11-08T12:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T12:46:19+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/south-africa-becomes-a-key-player-in-astrazeneca-s-global-clinical-trial-success 2024-11-08T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/meeting-highlights-from-the-committee-for-veterinary-medicinal-products-cvmp-5-7 2024-11-08T12:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-s-prosense-cancer-treatment-wins-crucial-fda-panel-vote-shares-surge 2024-11-08T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-sglt2i-drugs-are-safe-for-patients-with-cirrhosis-consult-qd 2024-11-08T12:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/who-announces-priority-endemic-pathogens-for-urgent-vaccine-development-pmlive 2024-11-08T12:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-markets-insider 2024-11-08T12:24:49+00:00 weekly 0.7 https://trial.medpath.com/news/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T12:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/the-uk-developed-handheld-scanner-that-could-revolutionise-medical-imaging-the-engineer 2024-11-08T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-globenewswire 2024-11-08T12:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-pr-newswire 2024-11-08T12:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T11:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-care-evolution-industry-leaders-address-quadruple-aim-challenges-and-opportunities 2024-11-08T11:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-provides-business-update-with-third-quarter-2024-financial-results-globenewswire 2024-11-08T11:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-pharmaceutical-co-ltd-submits-new-drug-application-to-the-u-s-fda-for-marketscreener 2024-11-08T11:43:36+00:00 weekly 0.7 https://trial.medpath.com/news/babyfox-study-to-assess-impact-of-ultrafast-whole-genome-sequencing-on-nicu-care-for 2024-11-08T11:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/dicot-pharma-announces-initiation-of-phase-2a-clinical-study-cision-news 2024-11-08T11:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T11:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/novel-dll3-topabody-shows-promising-preclinical-results-for-small-cell-lung-cancer-treatment 2024-11-08T11:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-of-multi-tyrosine-kinase-inhibitor-esk981-in-combination-with-pd-1-urotoday 2024-11-08T11:30:23+00:00 weekly 0.7 https://trial.medpath.com/news/a-36-gene-predictive-score-of-anti-cancer-dru-eurekalert 2024-11-08T11:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T11:21:31+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-underway-for-a-clinical-trial-testing-new-vaccine-against-respiratory-viruses 2024-11-08T11:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-suggests-removing-nonprescription-decongestant-from-market 2024-11-08T11:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-announces-successful-completion-of-end-of-phase-2-meeting-with-fda-for 2024-11-08T11:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/radella-reports-positive-outcomes-from-trial-of-md-18-for-obesity-and-diabetes 2024-11-08T11:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/smallpox-drug-in-clinical-trials-for-treating-mpox-in-africa 2024-11-08T10:41:32+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T10:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/ncc-premia-paradigm-unveil-nationwide-clinical-trial-network-in-japan-healthcare-asia 2024-11-08T10:10:52+00:00 weekly 0.7 https://trial.medpath.com/news/determining-doses-for-backfill-cohorts-based-on-patient-reported-outcome 2024-11-08T09:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/da-expects-approval-of-asf-vaccine-for-commercial-use-by-yearend-abs-cbn-news 2024-11-08T09:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-markers-linked-to-cognitive-decline-in-multiple-sclerosis-patients-study-finds 2024-11-08T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-rises-after-asthma-medicine-meets-primary-goals-in-phase-3-trial-tradingview 2024-11-08T08:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-hails-positive-phase-iii-data-for-repurposed-asthma-treatment-lse-azn 2024-11-08T07:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/industry-leaders-unite-to-tackle-patient-recruitment-challenges-in-rare-disease-clinical-trials 2024-11-08T07:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/wvu-cancer-institute-first-to-use-fda-approved-device-for-esophageal-cancer-prevention 2024-11-08T07:49:23+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-tipranks-com 2024-11-08T07:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/combining-the-vigex-gene-expression-signature-eurekalert 2024-11-08T07:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/dr-ashraf-on-the-utility-of-t-dxd-in-her2-mutated-nsclc-onclive 2024-11-08T07:23:43+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T07:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/fox-chase-cancer-center-appoints-renowned-immunotherapy-expert-dr-lorenzo-galluzzi-as-associate-professor 2024-11-08T07:08:52+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T07:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/ciie-helping-gilead-sciences-boost-development-in-china-chinadaily-com-cn 2024-11-08T06:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/skye-bioscience-reports-progress-in-obesity-drug-trials-tipranks-com 2024-11-08T06:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-therapeutics-interim-report-q3-2024-mfn-placera 2024-11-08T06:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-how-patients-and-scientists-team-up-to-fight-cancer-north-bay-news 2024-11-08T06:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/positive-outlook-and-buy-rating-for-protagonist-therapeutics-based-on-promising-phase-iii 2024-11-08T05:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-fda-finally-moves-to-pull-ineffective-decongestant-off-shelves-ars-technica 2024-11-08T05:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-johnson-johnson-s-device-for-heart-condition-et-healthworld 2024-11-08T05:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-adds-new-warning-to-weight-loss-drugs-including-wegovy-dallas-morning-news 2024-11-08T05:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-of-j-j-s-varipulse-ramps-up-pfa-competition-bioworld 2024-11-08T04:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/nebraska-medicine-finds-success-with-first-of-its-kind-cancer-treatment-wowt 2024-11-08T04:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-reports-third-quarter-2024-financial-results-biospace 2024-11-08T04:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/lupus-breakthrough-as-groundbreaking-new-nhs-therapy-could-offer-cure-for-it-and-ms 2024-11-08T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/palleon-pharmaceuticals-presents-results-from-the-phase-1-2-glimmer-01-trial-of-e-602-in-combination-with-cemiplimab-in-patients-with-solid-tumors-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting 2024-11-08T03:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2024-11-08T03:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/dr-pedro-martinez-clark-founder-of-amavita-heart-and-vasculartm-partners-with-limflow 2024-11-08T03:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-s-endoxifen-shows-promise-in-reducing-mammographic-breast-density-in-phase-ii-trial 2024-11-08T02:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/sec-recommends-marketing-approval-for-dr-reddy-s-spms-drug-siponimod-tablets 2024-11-08T02:29:20+00:00 weekly 0.7 https://trial.medpath.com/news/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher-motley-fool 2024-11-08T02:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/xilio-therapeutics-announces-initial-clinical-trial-data-globenewswire 2024-11-08T02:16:07+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-08T02:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-initiates-biomarker-cohort-in-phase-1-2-fortitude-trial-seeks 2024-11-08T02:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-china-president-detained-amid-widening-investigation-into-drug-related-violations 2024-11-08T01:45:11+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-reports-first-quarter-fiscal-2025-financial-results-and-provides-business-update 2024-11-08T01:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/data-from-transgene-and-nec-confirm-proof-of-principle-for-cancer-vaccine-tg4050 2024-11-08T01:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-opens-first-australian-site-for-azer-cel-clinical-trial-targeting-lymphoma 2024-11-08T00:51:58+00:00 weekly 0.7 https://trial.medpath.com/news/dr-parikh-on-available-treatment-options-for-her2-crc-onclive 2024-11-08T00:40:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-powell-on-the-implications-of-the-fda-approval-of-dostarlimab-for-endometrial-cancer 2024-11-08T00:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/three-patient-receive-groundbreaking-lupus-treatment-in-the-uk-the-independent 2024-11-08T00:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-benmelstobart-plus-anlotinib-and-chemotherapy-in-advanced-or-metastatic-nature 2024-11-08T00:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus-wandsworth-times 2024-11-08T00:13:52+00:00 weekly 0.7 https://trial.medpath.com/news/news-events-pilatus-biosciences 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-insights-into-til-therapy-a-new-horizon-in-cancer-treatment 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/huons-acquires-31-53-stake-in-pangen-biotech-for-10-4-million-to-advance-biopharmaceutical-cdmo-business 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-nhs-data-access-barriers-impede-critical-medical-research-sudlow-review-warns 2024-11-07T23:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/emory-study-estimates-millions-with-depression-could-benefit-from-psychedelic-mushrooms 2024-11-07T23:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-hiv-combination-antiretroviral-medication-in-black-individuals-contagion-live 2024-11-07T23:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/vanda-seeks-new-markets-for-hetlioz-amid-generic-competition-sleep-review 2024-11-07T23:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/89bio-inc-sec-10-q-report-tradingview 2024-11-07T23:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/esperion-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T23:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-provides-business-and-clinical-update-and-reports-third-quarter 2024-11-07T23:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-07T22:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-holdings-inc-sec-10-q-report-tradingview 2024-11-07T22:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-gains-fda-approval-for-varipulse-pfa-system 2024-11-07T22:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-07T22:13:21+00:00 weekly 0.7 https://trial.medpath.com/news/ecog-acrin-and-precog-announce-multiple-presentations-at-ash-2024-eurekalert 2024-11-07T22:00:38+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-work-on-next-gen-exon-skipping-drug-for-duchenne-endpoints-news 2024-11-07T21:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/field-medical-s-fieldforce-pfa-system-receives-fda-breakthrough-designation-for-ventricular-tachycardia-treatment 2024-11-07T21:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/vistagen-reports-fiscal-year-2025-second-quarter-financial-results-and-corporate-update 2024-11-07T21:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-reports-third-quarter-2024-financial-results-markets-data 2024-11-07T21:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/profound-medical-announces-third-quarter-2024-financial-results-globenewswire 2024-11-07T21:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/rocket-pharmaceuticals-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T21:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-07T21:16:12+00:00 weekly 0.7 https://trial.medpath.com/news/iovance-biotherapeutics-reports-financial-results-and-globenewswire 2024-11-07T21:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-holdings-inc-reports-third-quarter-2024-financial-results-stock-titan 2024-11-07T21:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-07T21:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-reports-third-quarter-2024-financial-results 2024-11-07T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights 2024-11-07T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-07T21:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-reports-third-quarter-2024-financial-results-and-highlights-recent-progress 2024-11-07T21:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/intravitreal-implant-could-transform-wet-amd-treatment-medpage-today 2024-11-07T20:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-scraps-a-duchenne-drug-as-gene-therapy-sales-rise-biopharma-dive 2024-11-07T20:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-shows-promise-in-small-phase-2-trial 2024-11-07T20:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-proposes-banning-oral-phenylephrine-in-decongestants-ny1 2024-11-07T20:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-aims-to-enter-glp-1-market-with-different-drug-approach-insidehealthpolicy-com 2024-11-07T20:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaking-clinical-data-and-real-world-evidence-presented-at-hiv-glasgow-as-gilead 2024-11-07T20:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-protocol-as-a-pointer-to-the-claimed-crystalline-form-of-a-compound-t-1152-21 2024-11-07T20:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-trial-launched-through-gates-institute-packages-two-cars-in-one-treatment 2024-11-07T20:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/new-dual-target-drug-shows-promise-against-bladder-cancer-jonathan-rosenberg 2024-11-07T20:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-globenewswire 2024-11-07T19:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/curasight-a-s-publishes-clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients 2024-11-07T19:25:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-removes-clinical-holds-previously-placed-on-3-of-carsgen-s-oncology-cell-therapies 2024-11-07T19:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/the-promise-of-personalized-neurostimulation-in-slowing-alzheimer-progression-neurology-live 2024-11-07T19:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-type-c-meeting-to-discuss-paxalisib-pathways-in-glioblastoma 2024-11-07T19:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-announces-successful-completion-of-end-of-phase-2-globenewswire 2024-11-07T18:56:02+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/marvel-biosciences-announces-mb204-outperforms-approved-drug-trofinetide-in-a-biospace 2024-11-07T18:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/trauma-patients-could-be-enrolled-without-consent-in-study-of-drugs-to-prevent-blood-loss 2024-11-07T18:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-pulls-plug-on-duchenne-exon-skipping-drug-pharmaphorum 2024-11-07T18:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T18:18:35+00:00 weekly 0.7 https://trial.medpath.com/news/assessing-phase-2-data-on-bepranemab-s-effect-on-tau-accumulation-and-cognitive-function 2024-11-07T18:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/kwality-pharma-received-approval-for-leuprorelin-acetate-for-injectable-suspension-from-greece 2024-11-07T17:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-align-trial-shows-atrasentan-significantly-reduces-proteinuria-in-high-risk-iga 2024-11-07T17:38:56+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-07T17:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/review-clinical-trials-show-cannabis-improves-symptoms-in-fibromyalgia-patients 2024-11-07T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-suggests-removing-oral-phenylephrine-as-otc-monograph-nasal-decongestant-ingredient 2024-11-07T17:23:16+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents 2024-11-07T17:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/study-explores-underpinnings-of-immunotherapy-releated-myocarditis-in-patients-with-cancer 2024-11-07T17:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-wins-fda-approval-for-varipulse-pfa-system-medtech-dive 2024-11-07T17:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-mb-108-for-malignant-glioma-onclive 2024-11-07T17:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-s-mhb039a-shows-promise-in-phase-i-trial-for-solid-tumours 2024-11-07T16:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-and-nec-present-new-data-confirming-clinical-globenewswire 2024-11-07T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/designing-inclusive-clinical-trials-in-an-effort-to-upend-the-hiv-epidemic-gilead-sciences 2024-11-07T16:42:05+00:00 weekly 0.7 https://trial.medpath.com/news/emrosi-new-rosacea-treatment-option-approved-by-the-fda-webmd 2024-11-07T16:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-next-generation-duchenne-drugs-stat-news 2024-11-07T16:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/padeliporfin-vtp-maintains-robust-responses-and-is-safe-in-low-grade-upper-tract 2024-11-07T16:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-starts-trial-of-silmitasertib-in-children-with-difficult-to-treat-cancers 2024-11-07T16:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-places-clinical-hold-on-epilepsy-agent-rap-219-for-diabetic-peripheral-neuropathic-pain 2024-11-07T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/eque-cel-car-t-shows-strong-results-for-multiple-myeloma 2024-11-07T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-enlighted-trial-padeliporfin-vtp-shows-promise-in-low-grade-utuc 2024-11-07T16:03:26+00:00 weekly 0.7 https://trial.medpath.com/news/schizophrenia-pharmacology-version-2-0-psychiatric-times 2024-11-07T16:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/sitc-study-finds-io102-io103-vaccine-plus-pembrolizumab-active-in-patients-with-non 2024-11-07T15:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-07T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/postoperative-tumor-bed-radiation-versus-t-shaped-field-radiation-in-the-treatment-of-locally 2024-11-07T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-varipulse-platform-for-treatment-of-atrial-fibrillation-hcplive 2024-11-07T15:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-sanofi-regeneron-s-dupixent-for-young-eoe-patients-yahoo 2024-11-07T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/u-k-study-shows-most-cancer-patients-would-benefit-from-pharmacogenetic-testing 2024-11-07T15:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/uganda-phase-ii-of-mass-polio-vaccination-kicks-off-allafrica-com 2024-11-07T15:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T15:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/nektar-and-collaborators-present-late-breaking-results-from-phase-2-study-of-nktr-255 2024-11-07T15:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T15:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-plus-pembrolizumab-leads-to-shifts-in-frontline-metastatic-urothelial 2024-11-07T15:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/imunon-presents-positive-data-from-phase-2-ovation-2-globenewswire 2024-11-07T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-biospace 2024-11-07T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/vidac-pharma-receives-reinvestment-from-shareholders-to-drive-clinical-trials-of-its-cancer 2024-11-07T14:59:32+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-halts-development-of-next-gen-dmd-drug-reports-robust-elevidys-sales 2024-11-07T14:58:05+00:00 weekly 0.7 https://trial.medpath.com/news/tacrolimus-linked-to-lower-acute-gvhd-risk-american-journal-of-managed-care 2024-11-07T14:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-biospace 2024-11-07T14:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-biospace 2024-11-07T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-reports-third-quarter-2024-financial-results-biospace 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-biospace 2024-11-07T14:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/pepgen-inc-sec-10-q-report-tradingview 2024-11-07T14:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-07T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lbl-034-in-multiple-myeloma-targeted-oncology 2024-11-07T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-decide-on-spn-830-apomorphine-pump-approval-feb-1-parkinson-s-news-today 2024-11-07T14:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-laneo-mdma-for-clinical-trial-at-yale-globenewswire 2024-11-07T14:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-reports-2024-q3-financial-results-and-provides-corporate-update 2024-11-07T14:31:18+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-wins-fda-nod-for-varipulse-pfa-massdevice 2024-11-07T14:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-how-cancer-immunotherapy-leads-to-deadly-form-of-heart-inflammation-in 2024-11-07T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/rome-therapeutics-to-present-data-supporting-line-1-reverse-transcriptase-inhibitors-as 2024-11-07T14:19:32+00:00 weekly 0.7 https://trial.medpath.com/news/addressing-informative-censoring-bias-in-clinical-trials-targeted-oncology 2024-11-07T14:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/adipo-therapeutics-presents-positive-study-results-about-potential-obesity-treatment-news 2024-11-07T14:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates-markets-insider 2024-11-07T13:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/how-improvements-in-us-fda-regulatory-process-and-procedures-led-to-the-drug-approval 2024-11-07T13:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/driving-pan-african-research-collaboration-panther-and-africa-cdc-launch-the-mpox 2024-11-07T13:52:55+00:00 weekly 0.7 https://trial.medpath.com/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-oncolytic 2024-11-07T13:51:35+00:00 weekly 0.7 https://trial.medpath.com/news/palisade-bio-launches-phase-1-trial-for-novel-ulcerative-colitis-drug-pali-2108 2024-11-07T13:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-nears-alzheimer-s-drug-trial-results-investing-com 2024-11-07T13:38:58+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-beats-q3-expectations-fueled-by-hiv-drug-sales-raises-full-year-guidance 2024-11-07T13:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/q32-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T13:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-antibody-drug-conjugates-market-drugs-approval-price-sales-clinical-trials 2024-11-07T13:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/lung-cancer-awareness-month-2024-looking-back-at-progress-for-cell-and-gene-therapy 2024-11-07T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-initiates-biologics-license-application-of-pika-rabies-vaccine-to-the 2024-11-07T13:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T13:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-s-cancer-drug-shows-73-survival-rate-fda-agrees-on-pd-l1-biomarker-use 2024-11-07T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/rome-therapeutics-to-present-data-supporting-line-1-reverse-globenewswire 2024-11-07T13:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/magea4-opens-the-door-for-engineered-cellular-therapies-in-solid-tumors-onclive 2024-11-07T13:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/imunon-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T13:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-receives-fda-approval-for-the-varipulsetm-pulsed-field 2024-11-07T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/movano-health-announces-completion-of-clinical-study-with-cuffless-rf-blood-pressure-device 2024-11-07T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/castle-boasts-melanoma-test-s-capacity-to-reduce-unnecessary-testing-clinical-trials-arena 2024-11-07T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/moonlake-immunotherapeutics-sec-10-q-report-tradingview 2024-11-07T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/olanzapine-for-young-people-with-anorexia-nervosa-open-results-of-a-feasibility-study 2024-11-07T12:40:28+00:00 weekly 0.7 https://trial.medpath.com/news/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-mondaq 2024-11-07T12:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-regeneron-s-dupixent-approved-by-ec-for-younger-eosinophilic-oesophagitis-patients 2024-11-07T12:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-awarded-second-patent-for-et-400-hydrocortisone-oral-solution 2024-11-07T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-07T12:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T12:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-dupixent-for-treating-eosinophilic-esophagitis-in-young-children 2024-11-07T12:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-morningstar 2024-11-07T12:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-presents-updated-interim-phase-3-data-from-globenewswire 2024-11-07T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-reports-third-quarter-2024-financial-results-globenewswire 2024-11-07T12:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/drug-giants-display-advanced-technologies-solutions-at-ciie-chinadaily-com-cn 2024-11-07T11:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-secures-30-million-in-debt-funding-globenewswire 2024-11-07T11:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-biopharma-corp-abus-q3-2024-earnings-call-highlights-promising-clinical-trials-and 2024-11-07T11:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-enrols-first-subject-in-phase-i-ii-trial-of-silmitasertib-for-solid-tumours 2024-11-07T11:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/cerebral-near-infrared-spectroscopy-guided-neonatal-intensive-care-management-for-the-nature 2024-11-07T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/using-abortion-pills-very-early-in-pregnancy-is-safe-study-finds 2024-11-07T11:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-shows-effectiveness-in-curbing-anorexia 2024-11-07T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-wave-of-trials-in-huntington-s-disease-bring-hope-to-the-neurology-today 2024-11-07T11:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/qutenza-r-phase-iii-clinical-trial-for-post-surgical-neuropathic-pain-successfully-enrolls 2024-11-07T10:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-regeneron-dupixent-approved-in-eu-for-young-children-with-eosinophilic-esophagitis 2024-11-07T10:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy-yahoo-finance 2024-11-07T10:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare 2024-11-07T10:22:18+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy 2024-11-07T10:21:34+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical-trial-with 2024-11-07T10:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/inquis-raises-40m-for-pivotal-trial-of-clot-removal-device 2024-11-07T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-used-to-reduce-brain-damage-may-triple-death-risk-study-news18 2024-11-07T09:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/emergent-biosolutions-supports-new-clinical-trial-globenewswire 2024-11-07T09:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-dupixent-for-young-eoe-patients-pharmaceutical-technology 2024-11-07T09:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-to-present-updates-from-early-access-program-at-the-2024-ash-annual 2024-11-07T09:44:21+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T09:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-07T08:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-dupixent-to-treat-eosinophilic-esophagitis-in-children-as-young-as-one-year 2024-11-07T08:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-trk-inhibitors-show-promise-in-treating-ntrk-fusion-positive-cancers 2024-11-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-to-present-more-than-40-abstracts-across-nine-blood-disorders-at-the-66th-ash-meeting 2024-11-07T07:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T07:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-asa-fra-7um-q3-2024-earnings-call-highlights-strat-gurufocus 2024-11-07T07:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-vpag-scheme-launches-new-metrics-framework-to-track-pharmaceutical-access-and-pricing 2024-11-07T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-07T06:43:21+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-07T06:42:56+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-to-present-new-phase-2-data-on-iopofosine-i-131-for-waldenstroms-macroglobulinemia-at-ash-2024 2024-11-07T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/doctors-in-australia-lead-phase-3-theranostics-study-targeting-advanced-prostate-cancer 2024-11-07T06:39:39+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-cision-news 2024-11-07T06:08:25+00:00 weekly 0.7 https://trial.medpath.com/news/scope-of-things-scope-europe-2024-ai-in-clinical-trials-rising-stars-more 2024-11-07T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/adopting-broader-clinical-trial-eligibility-in-lung-cancer-with-brain-mets-leptomeningeal-disease 2024-11-07T05:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-expands-genetic-testing-guidelines-to-include-prostate-cancer-and-updates-multi-cancer-risk-assessment 2024-11-07T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-hemophilia-treatments-show-promise-for-joint-health-while-access-barriers-persist-globally 2024-11-07T05:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-reports-q3-results-and-drug-progress-tipranks-com 2024-11-07T05:14:35+00:00 weekly 0.7 https://trial.medpath.com/news/rna-editing-promises-to-go-where-dna-editing-can-t-the-hindu 2024-11-07T04:54:59+00:00 weekly 0.7 https://trial.medpath.com/news/alcon-s-digital-transformation-success-clinical-trial-platform-drives-35-faster-database-delivery 2024-11-07T04:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/case-study-suggests-some-men-with-advanced-prostate-cancer-could-benefit-from-t-dxd 2024-11-07T04:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/cyramza-tagrisso-combo-prolongs-pfs-in-some-patients-with-nsclc-subset-cure-today 2024-11-07T04:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-face-uncertain-future-under-potential-trump-administration 2024-11-07T03:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-receives-fda-rare-pediatric-disease-and-orphan-drug-designations-for-ab-1003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9 2024-11-07T03:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-botox-cosmetic-s-fda-approval-may-lead-to-higher-visibility-more-patient-inquiries 2024-11-07T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/grand-rounds-november-22-2024-tranexamic-acid-in-patients-undergoing-liver-resection 2024-11-07T02:45:58+00:00 weekly 0.7 https://trial.medpath.com/news/radiotherapy-manchester-scientists-use-ai-to-simulate-cancer-patient-trials-bbc 2024-11-07T02:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol-trials 2024-11-07T02:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-cision-news 2024-11-07T01:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-data-support-efficacy-safety-of-new-schizophrenia-drug-medpage-today 2024-11-07T01:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-s-scd-wins-4th-fda-breakthrough-status-targets-48b-dialysis-market 2024-11-07T01:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-07T01:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T00:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/blackstone-s-proposed-acquisition-of-i-rom-raises-concerns-accc 2024-11-07T00:34:44+00:00 weekly 0.7 https://trial.medpath.com/news/huidagene-therapeutics-crispr-cas13-rna-editing-therapy-hg202-gets-cgtlive-r 2024-11-07T00:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/jama-oncology-publishes-phase-1b-2-study-data-on-iaso-bio-s-equecabtagene-autoleucel-fucasotm-in-the-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-07T00:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-interview-with-president-and-ceo-frank-bedu-addo-about-the 2024-11-07T00:04:24+00:00 weekly 0.7 https://trial.medpath.com/news/north-texas-caris-life-sciences-gets-fda-approval-for-its-mi-cancer-seek-companion 2024-11-07T00:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-discovery-news 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T23:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/elan-stock-report-elanco-animal-health-investors-are-globenewswire 2024-11-06T23:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-biospace 2024-11-06T23:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-shockwave-medical-shares-first-clinical-outcomes-associated-with 2024-11-06T23:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/severe-asthma-clinical-trial-pipeline-appears-robust-with-40-key-pharma-companies 2024-11-06T22:45:13+00:00 weekly 0.7 https://trial.medpath.com/news/sab-bio-announces-third-quarter-2024-financial-results-and-provides-company-update 2024-11-06T22:18:42+00:00 weekly 0.7